CTS Corporation Delivers Broad-Based Growth, Narrows Outlook

CTS Corporation ((CTS)) has held its Q1 earnings call. Read on for the main highlights of the call.

CTS Corporation’s latest earnings call struck a notably upbeat tone, underscoring strong execution on its diversification strategy and broad-based growth across key end markets. Management highlighted expanding margins, robust bookings and backlog, and continued capital returns, while acknowledging manageable headwinds from input-cost inflation, aerospace and defense timing, and geopolitical uncertainty.

Revenue Growth

CTS posted Q1 sales of $139 million, up 11% year-over-year and 1% sequentially, underscoring solid momentum to start the year. Diversified end markets were the standout, with sales up 18% versus a modest 3% rise in transportation, reinforcing the company’s pivot away from auto cyclicality.

Medical Market Outperformance

Medical revenue surged to $25 million, a 28% year-over-year increase, supported by strong demand in therapeutic and aesthetics applications. Bookings climbed 18% and a 1.2 book-to-bill ratio gives management confidence to project continued double-digit growth as added capacity comes online.

Industrial Momentum

Industrial sales reached $37 million, up 14% from a year earlier, driven by recovering OEM and distribution channels. Bookings rose 28% with a book-to-bill of 1.29, up from 1.15 previously, powered by wins in printing, flow meters, and temperature sensing.

Transportation Stability and Wins

Transportation revenue of $60 million grew 3% year-over-year and 7% sequentially, showing resilience despite macro uncertainty in light vehicles. New awards in current sensing, foot controls in Europe, and accelerometers for a North American OEM bolster CTS’s sensor and footwell portfolio for future programs.

Gross Margin Expansion

Adjusted gross margin improved to 39.5%, an increase of 250 basis points year-over-year and 40 basis points sequentially. Management credited operational improvements and a favorable mix toward higher-value medical and industrial business for the margin gains.

Profitability Improvement

Adjusted diluted EPS climbed to $0.62 from $0.44 a year ago, a roughly 41% jump that outpaced revenue growth. GAAP diluted EPS rose to $0.59 from $0.44, reflecting stronger profitability as cost discipline and mix benefits flowed through the P&L.

Strong Bookings and Backlog

The company posted a solid company-wide book-to-bill of 1.1, up about 4% versus last year, with particular strength in industrial and medical orders. Total booked business stands at roughly $1.1 billion, giving CTS good revenue visibility beyond the current quarter.

Large Defense Opportunity Win

CTS secured a significant underwater hull penetrator program, with potential contract value of about $20 million over five years. Additional naval sonar and RF filter wins, along with two new RF filter customers, deepen its presence in specialized defense applications despite near-term booking softness.

Cash Generation and Capital Returns

Year-to-date operating cash flow came in at $17 million, supporting a cash balance of $91 million against borrowings of $63 million. The company returned $10 million to shareholders through dividends and buybacks, repurchasing roughly 177,000 shares and leaving $82 million on its authorization.

Aerospace & Defense Booking Weakness

Management acknowledged that aerospace and defense bookings were down year-over-year, with a book-to-bill below one in Q1. They attributed the softness to timing and lumpiness in government funding and expect order activity to improve in the second half.

Inflationary and Input-Cost Pressures

Rising costs for precious metals, oil-derived materials like resins and epoxies, and transportation are emerging as headwinds into Q2. CTS is working closely with customers and suppliers on pricing and sourcing strategies to offset these pressures and protect margins.

Geopolitical and Macro Uncertainty

The company cautioned that geopolitical tensions could weigh on global growth and light-vehicle demand in the second half of the year. External forecasts point to softer automotive production in key regions, adding another layer of risk to transportation volumes.

Tariff and Policy Risk

CTS is monitoring potential changes to steel and aluminum tariffs that could affect its cost base and pricing. Management stressed the need for agility and indicated it is prepared to adjust pricing and supplier relationships if policy shifts squeeze margins.

Currency and One-Time Effects

Foreign exchange provided a roughly $3 million lift to Q1 sales and about $0.7 million to gross margin, temporarily boosting reported results. Executives warned these FX tailwinds could reverse, introducing volatility to future quarters despite underlying operational strength.

Debt and Cash Timing

Borrowings ticked up by about $5 million in Q1, largely due to timing of incentive compensation payments, buybacks, and slightly higher capital spending. While operating cash flow of $17 million is positive, it was modest relative to shareholder returns and investment levels, warranting continued balance-sheet discipline.

Guidance and Outlook

CTS narrowed full-year 2026 sales guidance to $560–$580 million and adjusted EPS to $2.35–$2.45, signaling confidence under current market conditions. Management expects ongoing strength in medical and industrial, slightly lower transportation volumes with commercial vehicle improvement later in the year, and a recovery in aerospace and defense bookings in the second half.

CTS’s earnings call painted a picture of a company successfully shifting toward diversified, higher-margin markets while staying vigilant about external risks. Investors heard a blend of solid execution, disciplined capital allocation, and realistic caution, with narrowed guidance and a strong backlog suggesting the growth story remains intact despite a choppy macro backdrop.